PDGFRB and hepatocellular carcinoma: In a limited subset of patients with HCC, lenvatinib, an oral tyrosine kinase inhibitor that targets FGFR1–4, VEGFR1–3, KIT RET, and PDGFR-beta has generated partial responses.